-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎ WuXi AppTec content team editor
Gritstone bio recently announced the results
The SLATE project is a cancer vaccine immunotherapy that uses engineered methods to deliver tumor neoantigens into patients to stimulate A T cell response (especially CD8+ toxin T cells) to attack tumors
The purpose of this Phase 1/2 trial is to test the safety, immunogenicity and early clinical efficacy
Image credit: 123RF
Data analysis showed that SLATE v1 showed consistent and strong immunogenicity with SLATE-KRAS vaccine, and the ex vivo enzyme-linked immune spot test (ELISpot) showed that 31% and 55% of patients treated with SLATE v1 and SLATE-KRAS triggered KRAS-specific CD8+ T cells
This therapy also shows good safety and tolerability, and most of the treatment-related adverse reactions are of class
"We are encouraged
WuXi AppTec provides integrated, end-to-end new drug development and production services to the global biopharmaceutical industry, covering chemical drug development and production, biological research, preclinical and clinical trial development, cell and gene therapy research and development, testing and production